FCRL6 | Fc receptor-like 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
FGD2 | FYVE, RhoGEF and PH domain containing 2 | Cytoskeleton related proteins
| | | | | Tissue enhanced |
FLJ00418 | | | | | | | Tissue enhanced |
FRZB | Frizzled-related protein | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
FUT7 | Fucosyltransferase 7 (alpha (1,3) fucosyltransferase) | | | | | | Tissue enhanced |
GFRA2 | GDNF family receptor alpha 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
GIMAP1 | GTPase, IMAP family member 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
GP9 | Glycoprotein IX (platelet) | CD markers Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
GPR182 | G protein-coupled receptor 182 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GRAPL | GRB2-related adaptor protein-like | | | | | | Tissue enhanced |
GSDMC | Gasdermin C | | | | | | Tissue enhanced |
GZMM | Granzyme M (lymphocyte met-ase 1) | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
HCAR3 | Hydroxycarboxylic acid receptor 3 | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
IGSF21 | Immunoglobin superfamily, member 21 | Predicted secreted proteins
| | | | | Tissue enhanced |
IGSF6 | Immunoglobulin superfamily, member 6 | Predicted membrane proteins
| | | | | Tissue enhanced |
IL2RB | Interleukin 2 receptor, beta | Cancer-related genes CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
ITGAX | Integrin, alpha X (complement component 3 receptor 4 subunit) | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KAZALD1 | Kazal-type serine peptidase inhibitor domain 1 | Predicted secreted proteins
| | | | | Tissue enhanced |
KAZN | Kazrin, periplakin interacting protein | | | | | | Tissue enhanced |
KCNB2 | Potassium voltage-gated channel, Shab-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNT1 | Potassium channel, subfamily T, member 1 | Disease related genes Potential drug targets Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KIF17 | Kinesin family member 17 | Plasma proteins
| | | | | Tissue enhanced |
KIR2DL3 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 3 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KIR2DL4 | Killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
KIR3DL1 | Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KIR3DL2 | Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KLRC3 | Killer cell lectin-like receptor subfamily C, member 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRC4 | Killer cell lectin-like receptor subfamily C, member 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRD1 | Killer cell lectin-like receptor subfamily D, member 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
KLRF1 | Killer cell lectin-like receptor subfamily F, member 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRA1 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LILRA2 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 2 | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
LILRA4 | Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LILRB1 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
LILRB5 | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
LIMD2 | LIM domain containing 2 | | | | | | Tissue enhanced |
LINGO3 | Leucine rich repeat and Ig domain containing 3 | Predicted membrane proteins
| | | | | Tissue enhanced |
LRRC25 | Leucine rich repeat containing 25 | Predicted membrane proteins
| | | | | Tissue enhanced |
MAATS1 | MYCBP-associated, testis expressed 1 | Mitochondrial proteins Predicted membrane proteins
| | | | | Tissue enhanced |
MADCAM1 | Mucosal vascular addressin cell adhesion molecule 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
MEFV | Mediterranean fever | Disease related genes
| | | | | Tissue enhanced |
MS4A7 | Membrane-spanning 4-domains, subfamily A, member 7 | Predicted membrane proteins
| | | | | Tissue enhanced |
MYCT1 | Myc target 1 | Predicted membrane proteins
| | | | | Tissue enhanced |
NCR1 | Natural cytotoxicity triggering receptor 1 | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
NDST3 | N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 | Enzymes
| | | | | Tissue enhanced |
NETO2 | Neuropilin (NRP) and tolloid (TLL)-like 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
NKG2-E | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
NKX2-3 | NK2 homeobox 3 | Transcription factors
| | | | | Tissue enhanced |